Inorganic, injectable and thermosensible cement for bone reconstruction: preparation and use. (Machi

专利摘要:
Inorganic cement, injectable and thermosensitive for bone reconstruction: preparation and use. Inorganic cement, injectable and thermosensitive for biomedical applications: preparation and use. It is proposed the preparation of an injectable thermosensitive cement with clinical applications in bone surgery and minimally invasive dentistry, based on self-hardening mixtures of magnesium oxide, calcium, sodium or ammonium phosphates, calcium carbonates, calcium sulfates or other inorganic salts with a poloxamer hydrogel. This cement has as main property a thermosensitive effect. Likewise, it presents a high cohesion in contact with fluids at physiological temperature, accompanied by a decrease in the force necessary for its injection with temperature. The use of cement for bone and dental applications is indicated, as well as the filling of bone defects. Cement is especially indicated in cases where a minimally invasive use is necessary. (Machine-translation by Google Translate, not legally binding)
公开号:ES2553302A1
申请号:ES201430644
申请日:2014-05-05
公开日:2015-12-07
发明作者:Edgar Benjamin MONTUFAR JIMENEZ；Yassine MAAZOUZ；David PASTORINO；Maria Pau Ginebra Molins
申请人:Universitat Politecnica de Catalunya UPC；
IPC主号:

专利说明:

5
10
fifteen
twenty
25
30
35
40
Four. Five
DESCRIPTION
Inorganic, injectable and heat sensitive cement for bone reconstruction: preparation and use. Field of the Invention
The present invention relates to biomaterials for the regeneration of hard tissues: bones and teeth. These materials can be prepared in the form of granules, cements, coatings, dense or porous ceramics, etc. Among other applications they can be applied to fill bone cavities, cranial defects or cavities after removing a tumor, filling empty spaces after a multiple fracture, filling gaps after removing a tooth, increasing the amount of bone before placing a dental implant, fix screws when metal plates are placed, stabilize bone fractures or cover prostheses and implants.
A completely injectable inorganic cement is proposed making it especially suitable for medical and veterinary procedures of minimal surgical invasion. However, it can also be used in traditional surgery. In particular, the cement has heat-sensitive properties, that is, certain properties such as cohesion, injection force or setting time can be modulated by controlling the temperature of the paste. On the other hand, the final product of the setting reaction, depending on the starting composition, can comprise calcium phosphates, such as hydroxyapatite, calcium deficient hydroxyapatite, brushite or monetite, with great compositional and structural similarity to the mineral phase of the bones and teeth, or other inorganic salts such as magnesium phosphates, calcium carbonates or calcium sulfates with a mechanical resistance suitable for bone and dental applications. Likewise, cement can act as a support for controlled drug delivery (Drug Delivery system) and for cell growth in tissue engineering (Tissue Engineerings scaffolds). The present invention also relates to methods for obtaining said biomaterials.
This invention also relates to a process for the preparation of said cement and the use of said cement for bone and dental applications.
State of the prior art
Since the mid-1980s, the scientific community has made important advances in the field of design and manufacturing of new materials for the replacement and regeneration of mineralized biological tissues. One type of materials that has been extensively studied are materials based on inorganic salts, such as calcium or magnesium phosphates, calcium sulfates or calcium carbonates. Among the different ways in which these materials can be presented, cements deserve special attention due to certain intrinsic advantages such as their moldability and perfect adaptation to the bone cavity, the possibility of injecting them using minimally invasive techniques and their ability to harden once implanted inside the body. It is noteworthy that in the case of calcium phosphate cements, it can be obtained as a product of the hydroxyapatite reaction, which has many similarities with the natural inorganic bone component, such as the chemical composition and the nanometric size of the crystals.
Recent developments in minimally invasive surgery have reduced the risk that the patient runs during the surgical intervention and the hospital's cost. This new surgical technique requires new fully injectable bone regeneration materials, capable of hardening in situ and regenerating damaged bone. Despite the recognized ability of inorganic cements to successfully fill and / or regenerate damaged bone, they also have certain limitations. First, the injectability of inorganic cement pastes is limited. Second, the setting time of injectable cements tends to be longer than that of non-injectable cements. Finally, the third limitation is the low mechanical resistance of injectable cements.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
The injectability of inorganic cements can be improved by increasing the ratio | [liquid-powder mixing. However, this alternative retards the setting of the cement, facilitates the disintegration of the paste when it comes into contact with a liquid medium and considerably reduces the mechanical resistance. Another alternative is the incorporation of a polymer, usually a hydrogel, into the liquid phase of the cement. In this case, the injectability and the cohesion of the pastes increase considerably but also the force required to inject the paste significantly increases. In addition, the incorporation of the hydrogel produces side effects such as the increase in the setting time and the decrease in mechanical resistance. The hydrogels used to improve the injectability of inorganic cements for biomedical use are mostly of natural origin such as cellulose and its derivatives, chitosan, collagen, gelatin, sodium alginate or hyaluronic acid. Precisely due to its natural origin, special care should be taken to avoid possible immunological rejections or variations in the properties between the different batches of the hydrogel.
A family of polymers of synthetic origin, and therefore without associated problems such as immunological rejection or the variability of their properties, are poloxamers. The poloxamers are copolymers of three blocks composed of a hydrophobic central part of poly (propylene oxide) flanked by two lateral hydrophilic parts of poly (ethylene oxide) [1]. Depending on the length of the three chains there are different types of poloxamers. In general, poloxamers are considered non-ionic surfactants. By increasing the concentration in water, the molecules of this copolymer are associated to form micelles and if the concentration continues to increase they are capable of forming hydrogels. The concentration at which the hydrogel is formed depends on the type of poloxamer and the temperature. In general, at low temperatures, poloxamer solutions have a low viscosity and behave like liquids, while at high temperatures their viscosity increases and they behave like hydrogels. The poloxamers are biocompatible, do not significantly alter biological functions and are excreted by the kidneys. For these reasons, poloxamers are used in a wide variety of biomedical applications as systems for the controlled release of drugs, excipients in medications or temporary embolizing agents, among many others [1].
In a very distant area of the development of inorganic cements for biomedical use in minimally invasive surgery, poloxamers have been used for their rheological characteristics in direct three-dimensional printing processes to form ceramic inks for the manufacture by robotic molding of scaffolding for tissue engineering . In particular, poloxamers have been mixed with non-reactive calcium phosphates such as bioactive glasses, hydroxyapatite, beta tricalcium phosphate or mixtures of the last two [2]. The fact that these inks do not have the ability to set like a cement has three important consequences. The first is that the time between mixing and printing the inks does not affect the force required for extrusion. The second is that the consolidation of the manufactured structures is done by sintering between 700 and 1400 ° C, which implies that although the compositional similarity with the mineral phase of the bones and teeth is maintained, the microstructural similarity is lost, producing difficult materials to reabsorb in vivo. Finally, manufactured scaffolds are rigid and have predefined shapes and sizes, so they cannot be implanted using non-invasive surgical techniques.
Due to their ability to gel when the temperature increases, their solubility in aqueous media, their biocompatibility and the ability to be excreted by the kidneys, poloxamer hydrogels are used as a temporary embolizing agent in the field of cardiovascular medicine [3]. However, the thermo-sensitive properties of poloxamers have not been exploited in orthopedic or oral surgery, much less in inorganic cement formulations for biomedical use. The use of poloxamers in calcium phosphate cements is limited to their surfactant character to avoid the addition of cement dust [4] or for the formation of foams [5].
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
Brief explanation of the invention
Unlike the mentioned works and patents, this invention presents an inorganic / organic hybrid cement of biomedical use whose properties such as cohesion, setting time and injectability can be modulated by controlling the temperature. The paste is based on the mixture of inorganic salts self-forgeable with water or aqueous solutions, with or without the addition of additives that accelerate or retard the setting of the cement, and the incorporation of a poloxamer in the liquid phase or in the solid phase, to provide the desired heat sensitive character. Cement applications are clinical, bone or dental applications, both traditional and minimally invasive surgery. Said cement has several intrinsic properties that give it special interest. The first characteristic of the material is that, regardless of the initial temperature of the paste, the cement has cohesion when it is injected into a medium whose temperature is 37 ° C. This feature makes it possible for the cement to set and harden in situ without disintegrating or undergoing any erosion. The second relevant feature is that cement pastes with poloxamer are fully injectable by applying lower forces than those used to inject acrylic cements, and do not present phase separation. The most important point to note is that the injection force decreases with the decrease in the temperature of the paste. The injection force reaches a minimum and remains constant below 15 ° C. In addition, the pastes have short setting times compared to other cements that incorporate hydrogels to improve injectability. The cement hardens either by the formation and cross-linking of crystals of the phases that occur in the setting reaction, or by the formation of an amorphous phase, which lead to an increase in mechanical strength.
All these characteristics as a whole make the cement presented here ideal for minimally invasive surgery where bone or dental lesions are required to be regenerated, but it is also suitable for traditional surgery, both in medicine and veterinary medicine. Modulating the injection force allows the surgeon to inject the material as accurately as possible and with minimal effort, while the cohesive of the paste will ensure the success of the surgical procedure, making the paste set in the desired position, reaching a reasonable mechanical resistance. and similar to trabecular bone. Finally, the cement setting product is completely biocompatible, and in some specific cases it can become osteoconductive and reabsorbable, so regeneration of the damaged tissue is guaranteed.
The composition of the material has been optimized in order to guarantee the aspects mentioned in the previous paragraph. The preparation of the cement requires a solid powder or phase composed of one or several inorganic salts and a liquid phase composed mainly of water or some biocompatible solvent where the poloxamer can be dissolved. The mixing of both phases can be carried out manually or in a high-energy mixer, at a temperature below or equal to room temperature. The temperature of the solid phase and / or of the liquid phase at the time of mixing may be equal to or less than 25 ° C, preferably less than 12 ° C. The paste obtained can be implanted directly in the patient by means of traditional surgery or it can be placed in a syringe to be implanted by minimally invasive surgery. Alternatively, the paste may be placed in a syringe or similar device for subsequent freezing, preferably at temperatures equal to or below -20 ° C, for storage, and subsequently preferably thawed at less than 12 ° C for use in the clinical application. Once the hardening cement paste is implanted in situ due to its good physiological temperature cohesion and it will produce a rigid body with compression resistance similar to that of the trabecular bone.
It is important to keep in mind that for the use of cement in vivo, the powder and liquid must have been previously sterilized. In addition, a work zone is required
5
10
fifteen
twenty
25
30
35
40
Four. Five
sterile to avoid contamination of the reagents at the time of preparation and introduction of the paste.
Detailed explanation of the invention
This invention presents a thermosensitive inorganic cement for bone and / or dental applications, both in medicine and in veterinary medicine. The cement in question has several specific properties that give it special interest. In order to enhance these properties, the material preparation conditions have been optimized, as detailed below.
Firstly, the cement object of this invention has thermosensitive properties, which have not been previously described in any other formulation of cement for biomedical use of calcium or magnesium phosphate, calcium carbonate or sulfate. In other words, certain properties of the cement paste, such as the injection force, the cohesion or the setting time, can be modulated by controlling the temperature of the paste. This is achieved without compromising the biocompatibility of the material by using a poloxamer as an additive in the cement formulation.
Secondly, even with a low liquid content in the paste and unlike other fully injectable cements that incorporate hydrogels in their liquid phase, the cement injection force presented in this invention is relatively low (~ 50 N) and easy to reach by injecting by hand. This is achieved because the injection force decreases as the paste temperature decreases. This property allows the surgeon to inject the material as accurately as possible and with minimal effort. The working temperatures to obtain the lowest injection forces are temperatures slightly below the ambient temperature of an operating room (preferably between -5 and 18 ° C), which can be easily achieved with the use of refrigeration systems, thermal baths, refrigerators or other similar or equivalent devices, easily accessible in hospitals, clinics or medical offices.
Thirdly, it is important to note that the cohesion of the cement pastes presented here increases with the increase in the temperature of the medium where they are injected. It is of particular interest that, regardless of the initial temperature, the cement pastes presented here have cohesion right after they are mixed and injected into a medium at physiological temperature (37 ° C). This ensures that once the cement paste is implanted in the patient's body, it will not disintegrate but will keep the shape and harden in vivo, guaranteeing the success of the surgical procedure.
Fourth, the setting time of the cement is acceptable for clinical applications, giving the surgeon enough time to implant the cement with good paste injectability, and hardens quickly once implanted. The hardening of the cement is due to two processes that act in parallel, one is the reaction of setting of the cement and the other is the gelation of the poloxamer with the increase in temperature due to body heat.
Fifth, the incorporation of the poloxamer does not affect the product of the cement setting reaction, which in the case of a calcium phosphate cement and depending on the specific composition of the cement can be calcium deficient hydroxyapatite, hydroxyapatite, brushite , monetite, or other calcium phosphate. In particular, these phosphates are similar to the mineral phase of bones and teeth. What makes calcium phosphate cements biocompatible, osteoconductive and resorbable, therefore they have great potential to regenerate hard tissue, bone and tooth lesions of any vertebrate. On the other hand, in the case of other inorganic bone cements, the setting product comprises magnesium phosphates, calcium carbonates, calcium sulfates or mixtures thereof. The setting product can be both crystalline and amorphous.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
Sixthly, the mechanical strength of the set cement may be higher than that of the trabecular bone. In particular, optimized cements have similar resistance to several commercially available inorganic bone cements (compressive strength of around 30 MPa).
The process of preparation of the cement object of this patent requires a powder composed of one or several inorganic salts capable of hardening by a setting reaction upon contact with the liquid phase. The liquid phase is preferably composed of water, poloxamer in solution and may or may not incorporate, as necessary, an additive to accelerate or retard the setting reaction. In addition to water, other biocompatible liquids can also be used where the poloxamer is soluble and the cement is capable of setting. Since the distribution of particle sizes of the cement powder is a parameter that controls the injectability of the pastes, the control of the particle size is a key factor of this invention. The optimum particle size to improve the injectability without delaying the setting, nor damaging the mechanical strength of the cement can be achieved preferably by grinding the powder components, both dry and wet, using a water-free liquid such as, ethanol or acetone, among others. The thermosensitive character of cement is achieved by incorporating poloxamer in solution in the liquid phase or in powder form in the solid phase of the cement. Any variety of poloxamer can be used depending on the particular properties that are to be achieved. The mixing of the powder with the liquid phase can be carried out at various liquid-powder ratios, although low ratios are preferred to improve the mechanical strength of the set cement, and at various mixing temperatures, preferably temperatures below room temperature to be able to incorporate more powder in the poloxamer solution. It is recommended that the temperatures of the solid phase and / or of the liquid phase before mixing be below 25 ° C and preferably below 12 ° C. Mixing can be done by hand or with a mechanical device of any kind. To obtain more homogeneous pastes in the shortest possible time, a high-energy mechanical mixing device of the planetary mixer type is preferred. The paste obtained can be implanted directly into the bone or dental lesion to be treated, or it can be placed inside a syringe or similar device for subsequent implantation by injection. Alternatively, once the paste is placed inside a syringe or similar device, it can be frozen, preferably at temperatures equal to or below -20 ° C, for storage, and subsequent defrosting, preferably at less than 12 ° C for use. in the clinical application.
Inorganic thermosensitive cements are of interest for bone and dental applications, both in medicine and in veterinary medicine, especially in situations where it is necessary to increase bone mass or fill a bone or dental cavity. These cements can be used to fill bone cavities, cranial defects or cavities after removing a tumor, fill empty spaces after a multiple fracture, fill gaps after removing a tooth, increase the amount of bone before placing a dental implant, fix screws when metal plates are placed, fix fracture fixation devices, stabilize bone fractures or cover prostheses and implants, among others. Likewise, the cement can act as a support for the controlled release of drugs (Drug Delivery system) or substrate for cell growth in tissue engineering (Tissue Engineerings scaffolds).
Preparation of a thermosensitive inorganic cement for biomedical use
In order to illustrate in a practical way the invention below, the possible reagents for the preparation of injectable and heat sensitive inorganic cements for biomedical use are indicated. However, the possibilities are not limited to these examples. In the case of calcium phosphate cements the powder phase of the cement comprises alpha tricalcium phosphate, mixtures of tetracalcium phosphate with anhydrous or dihydrated dicalcium phosphate, or mixtures of
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
beta tricalcium phosphate with anhydrous or hydrated monocalcium phosphate. For magnesium phosphate cements the powder phase of the cement comprises mixtures of magnesium oxide with a phosphate salt, such as sodium, potassium, ammonium phosphates or mixtures thereof. For calcium carbonate cements the powder phase of the cement comprises vaterite and / or amorphous calcium carbonate. For calcium sulfate cements the powder phase of the cement comprises calcium sulfate hemihydrate. In all the cases mentioned the powder phase is preferably at a temperature below 25 ° C, and more preferably below 12 ° C.
As the main component of the liquid phase, distilled water or double distilled water can preferably be used. Alternatively, water, aqueous saline solutions, simulated physiological fluids or other liquids where the poloxamer is soluble and the cement is capable of setting can be used. The poloxamer to be used can be any of the existing poloxamers although high molecular weight are preferred, without implying any limitation. The poloxamer can be incorporated as a fine ground powder into the cement powder, although its incorporation in solution in the liquid phase of the cement is preferred. To favor the thermosensitive effect of cement, it is preferred to use poloxamers at a concentration such that the gelation temperature of the solution is close to room temperature, such as poloxamer 407 between 10 and 30% by weight. The temperature of the liquid phase at the time of mixing should be below 25 ° C and preferably below 12 ° C.
In order to get a fully injectable paste, ace! As the maximum mechanical resistance of the cement, it is necessary to control the particle size of the reagents that make up the powder and the mixing protocol with the liquid phase. In the case of particle size, the optimum size can be achieved by grinding the powder, both dry and wet, in the latter case using a water-free liquid such as ethanol or acetone, among others. The particle size distribution of the powder may vary between 0.1 and 80 pm, but preferably it has to be less than 20 pm. Alternatively, a particle size separation can be performed after grinding to achieve the desired size distribution. The mixing of the powder with the liquid phase can be carried out at different liquid-powder ratios, between 0.15 and 1.0 mL / g. It is preferably recommended to use liquid-powder ratios between 0.2 and 0.4 mL / g to improve the mechanical strength of the cement. Mixing can be done by hand or by a mechanical device of any kind. To obtain more homogeneous pastes in the shortest possible time, a high-energy mechanical mixing device of the planetary mixer type is preferred. It is recommended that the solid phase and / or liquid phase temperatures before mixing be below 25 ° C and more preferably below 12 ° C. It is recommended that the mixing temperature is preferably between -5 and 20 ° C. Under these conditions a paste with workable consistency is obtained that can be implanted directly in the bone or dental injury, or it can be placed inside a syringe or similar device for subsequent implantation by injection. The time between preparation and implantation of the paste depends on the specific formulation of the cement and can vary between 5 to 60 minutes.
In reference to the thermosensitive character of the material and to minimize the force necessary to inject the cement, the temperature of the paste at the time of injection should be below 25 ° C. It is preferably recommended that the paste is between -5 and 20 ° C. Any available method to cool the paste can be used. As an example, without limiting the alternatives, refrigeration systems, thermal baths, refrigerators or other similar or equivalent devices can be used.
The paste, once placed inside a syringe or similar device, can also be frozen, preferably at temperatures equal to or lower than -20 ° C, for storage, and subsequently preferably thawed at less than 12 ° C for use. in the clinical application.
5
10
fifteen
twenty
25
30
35
40
Four. Five
It is important to keep in mind that for the utilization of cement in vivo, the powder and liquid must have been previously sterilized. In addition, a sterile work zone is required to prevent contamination of the reagents at the time of preparation and introduction of the paste.
Preferred Embodiments
The examples included below are described with the purpose of illustrating the invention in a practical manner, without the intention of limiting or restricting the specific compositions contained therein and the method of preparing the mixture of ingredients.
Example 1: Thermosensitive calcium phosphate cement: injection force control
150 g of alpha tricalcium phosphate were ground in an agate jar using a planetary mill and the following three grinding stages: 1) 450 rpm for 60 minutes with 10 30 mm diameter agate balls; 2) 500 rpm for 40 minutes with 10 30 mm diameter agate balls; 3) 500 rpm for 60 minutes with 100 10 mm diameter agate balls. 2.5 g of Na2HPO4 and 20 g of poloxamer 407 were dissolved in a total volume of 100 mL of distilled water. The dissolution of the components was carried out in a high-energy planetary mixer for 30 minutes at 3000 rpm using water at 4 ° C. The preparation of the paste consisted of mixing 5,714 g of the alpha tricalcium phosphate powder with 2 ml of the Na2HPO4 solution and poloxamer 407 previously cooled to 0 ° C. The mixing was carried out in a high-energy planetary mixer for 20 seconds at 1650 rpm.
The paste obtained was incorporated into a syringe of 5 mL capacity and with an opening of 2 mm in diameter. Before injecting the cement paste the syringes were placed for 15 minutes in a water bath at different temperatures, so that the temperature of the paste at the time of injection was 0, 7, 12, 15, 18 or 20 ° C The syringes at the indicated temperature were placed on a support to perform the injection test. This test consists of measuring the force necessary to inject the paste at a feed rate of the syringe plunger of 15 mm / min. The test was carried out in a universal mechanical testing machine (MTS Bionix 858). The result of the test is the injectability curve, which relates the force necessary to inject the paste at a constant speed depending on the displacement of the embolus, the latter expressed in percentage with respect to the maximum possible path.
Figure 1 shows the injection curves for the cement paste containing poloxamer 407 at 7 and 20 ° C. Figure 1 also shows the injection curves for the cement paste without poloxamer 407 at the same temperatures. Without poloxamer 407 the injection force did not change considerably between 7 and 20 ° C (approximate value of 20 to 50 MPa). Without poloxamer 407, the paste was partially injected, since the embolus only reached between 45% and 55% of the possible travel. The reason is the phenomenon known as phase separation or pressure filtration, which is that the liquid is injected through the powder, so the solid fraction inside the syringe increases during the test. The increase in the solid fraction in the syringe makes it increasingly difficult to inject the paste, requiring more strength for the injection. On the other hand, regardless of the temperature, with poloxamer 407 the cement paste was completely injected since the stroke reached the maximum possible distance and visually no remaining paste was observed inside the syringes. It is interesting to note that, although in all cases the pastes were injected completely, the force required to inject them was significantly different between 7 and 20 ° C.
Figure 2 summarizes the results of the force required to inject the thermosensitive cement pastes at different temperatures (0, 7, 12, 15, 18 and 20 ° C). The values are presented as average and standard deviation of at least three trials. Figure 2 shows that the force required to inject the paste decreases as the temperature decreases. It is noted
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
also that for pulp temperatures equal to or less than 12 ° C the force for injection is minimal, taking values between 30 and 60 MPa. At all temperatures, the cement pastes are completely injectable and do not present in any case phase separation signals.
Example 2: Thermosensitive calcium phosphate cement: pastes cohesion
150 g of alpha tricalcium phosphate were ground in an agate jar using a planetary mill and the following three grinding stages: 1) 450 rpm for 60 minutes with 10 30 mm diameter agate balls; 2) 500 rpm for 40 minutes with 10 30 mm diameter agate balls; 3) 500 rpm for 60 minutes with 100 10 mm diameter agate balls. 2.5 g of Na2HPO4 and 20 g of poloxamer 407 were dissolved in a total volume of 100 mL of distilled water. The dissolution of the components was carried out in a high energy planetary mixer for 30 minutes at 3000 rpm using water at 4 ° C. The preparation of the paste consisted of mixing 5,714 or 3,636 g of the alpha tricalcium phosphate powder with 2 mL of the Na2HPO4 solution and poloxamer 407 previously cooled to 0 ° C. The mixing was carried out in a high energy planetary mixer for 20 seconds at 1650 rpm.
Immediately the obtained paste was incorporated into a syringe of 5 mL capacity and with an opening of 2 mm in diameter. The syringes were placed for 15 minutes in a water bath at different temperatures, so that the temperature of the paste was 0, 7 or 18 ° C. Once the paste reached the desired temperature it was injected by hand in a Ringer solution (0.9% by weight of NaCl in water) at different temperatures between 0 and 37 ° C. The cohesion of the pastes determined visually for a maximum of 24 hours, sufficient time for the hardening of the cement.
Figure 3 shows images of the paste initially at 18 ° C and injected in Ringer's solution at temperatures between 0 and 37 ° C. It can be seen that by increasing the temperature of the Ringer's solution, the injected paste retains its extrusion shape better, indicating that the cohesion of the paste increases with the temperature of the medium where it is injected. In particular, at 37 ° C (physiological temperature), the retention of the cement form is complete, so it can be injected with the assurance that the cement retains its integrity in situ. Figure 4 shows that the initial paste temperature (0, 7 or 18 ° C) does not affect the cohesion of the cement when it is injected in Ringer's solution at 37 ° C. Figure 5 shows that cements without poloxamer 407 have no cohesion in Ringer's solution at 37 ° C. On the one hand, when a small amount of powder (3,636 g) is mixed with 2 mL of 2% Na2HPO4 solution by weight, the paste is so liquid that it disintegrates immediately upon contact with Ringer's solution. On the other hand, when the amount of dust is greater (5,714 g), the paste seems to have cohesion after the first hours in contact with the Ringer solution, but over time the extrusion form loses continuity, resulting in several macroscopic fragments that although they end up hardening do not maintain their original form. In contrast with poloxamer 407, the cement pastes harden while completely maintaining its shape for the two amounts of powder used.
Example 3: Thermosensitive calcium phosphate cement setting and hardening
150 g of alpha tricalcium phosphate were ground in an agate jar using a planetary mill and the following three grinding stages: 1) 450 rpm for 60 minutes with 10 30 mm diameter agate balls; 2) 500 rpm for 40 minutes with 10 30 mm diameter agate balls; 3) 500 rpm for 60 minutes with 100 10 mm diameter agate balls. 2.5 g of Na2HPO4 and 20 g of poloxamer 407 were dissolved in a total volume of 100 mL of distilled water. The dissolution of the components was carried out in a high energy planetary mixer for 30 minutes at 3000 rpm using water at 4 ° C. The preparation of the paste consisted of mixing 5,714 g of the alpha tricalcium phosphate powder with 2 mL of the Na2HPO4 solution and poloxamer 407 previously cooled to 0 ° C. The mixing was carried out in a high energy planetary mixer for 20 seconds at 1650 rpm.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
The initial and final setting times were measured by the Gilmore needle test, according to which the initial setting time is defined as the time elapsed from the moment the powder contacts the liquid, until a pressure of 0 , 3 MPa leaves no mark on the surface of the cement, while the final setting time is defined as the time elapsed from the moment the powder contacts the liquid, until a pressure of 5 MPa leaves no mark on The surface of the cement. The test was carried out by introducing the cement paste into cylindrical plastic molds 10 mm high. The initial setting time of the cement was 11.6 minutes and the final time was 33.7 minutes.
To determine the final product of the setting reaction and the compressive strength of the cement, cement specimens 12 mm high and 6 mm in diameter were prepared in teflon molds. These molds were introduced in Ringer's solution (0.9% by weight of NaCl in water) and kept at 37 ° C for 7 days. The X-ray diffraction diagram of the cement set for 7 days is presented in Figure 6. The maximum diffraction observed are consistent with the hydroxyapatite crystallographic record (JCPDS 09-0342). This indicates that during setting the tricalcium alpha phosphate is hydrolyzed to form hydroxyapatite. In particular, and according to the Ca / P ratio of alpha tricalcium phosphate used as a reagent (Ca / P = 1.5), the hydroxyapatite formed corresponds to a calcium deficient hydroxyapatite. The compressive strength was measured using a universal mechanical testing machine, with a 10 kN load cell, using a jaw displacement speed of 1mm / min. The compressive strength of the thermosensitive cement set was 28.4 ± 5.1 MPa. The skeletal density of the thermosensitive cement set by means of helium pycnometry was 2.68 g / cm3.
Example 4: Storage of low temperature cement paste: Freezing and defrosting
150 g of alpha tricalcium phosphate were ground in an agate jar using a planetary mill and the following three grinding stages: 1) 450 rpm for 60 minutes with 10 30 mm diameter agate balls; 2) 500 rpm for 40 minutes with 10 30 mm diameter agate balls; 3) 500 rpm for 60 minutes with 100 10 mm diameter agate balls. 2.5 g of Na2HPO4 and 20 g of poloxamer 407 were dissolved in a total volume of 100 mL of distilled water. The dissolution of the components was carried out in a high energy planetary mixer for 30 minutes at 3000 rpm using water at 4 ° C. The preparation of the paste consisted of mixing 5,714 g of the alpha tricalcium phosphate powder with 2 mL of the Na2HPO4 solution and poloxamer 407 previously cooled to 0 ° C. The mixing was carried out in a high energy planetary mixer for 20 seconds at 1650 rpm.
Immediately the obtained paste was incorporated into a syringe of 5 mL capacity and with an opening of 2 mm in diameter. The syringes were placed for 15 minutes in liquid nitrogen and immediately placed at -80 ° C in a freezer for 3, 7, 14, 21 and 49 days. After these times the syringes with the cement paste were thawed for 13 minutes in a water bath at 7 ° C. The force required to inject the defrosted cement paste was determined by the injection test. The test was performed on a universal mechanical testing machine (MTS Bionix 858) at a feed rate of the syringe plunger of 15 mm / min. Figure 7 shows that the force necessary to inject the defrosted cement pastes did not increase significantly (p> 0.05) with respect to the force necessary to inject the freshly prepared pasta at the same temperature. In all cases the paste was injected in its entirety since the embolus reached the end of the path and no remaining paste was observed in the syringes. Defrosted pastes showed total cohesion when injected in Ringer's solution (0.9% by weight of NaCl in water) at 37 ° C. The initial and final setting times, measured by the Gilmore needle test after the different freezing times, did not change significantly (p> 0.05) with respect to the initial and final setting times (respectively) of non-pasted pastes.
5
10
fifteen
twenty
25
30
35
40
frozen. Nor were statistically significant changes (p> 0.05) in the compressive strength of the cement set for 7 days due to the freezing and thawing of the cement paste.
Brief description of the figures
The following has been represented in the Figures:
Figure 1. Injection curves (force - stroke displacement) corresponding to cements with poloxamer 407 (continuous lines) at 7 and 20 ° C, and without poloxamer 407 (dashed lines) at 7 and 20 ° C.
Figure 2. Forces required to inject thermosensitive cement pastes at different temperatures (0, 7, 12, 15, 18 and 20 ° C).
Figure 3. Images of the cohesion of the thermosensitive cement pastes in Ringer's solution at temperatures between 0 and 37 ° C. In all cases the initial temperature of the paste was 18 ° C.
Figure 4. Images of the cohesion of the thermosensitive cement pastes initially maintained at 0, 7 or 18 ° C, when injected in a Ringer solution at 37 ° C.
Figure 5. Images of the cohesion of cement pastes with different amounts of powder and 2 mL of liquid phase, with and without the incorporation of poloxamer 407.
Figure 6. X-ray diffraction of the reaction product of a thermosensitive cement set in Ringer's solution for 7 days at 37 ° C.
Figure 7. Forces necessary to inject thermosensitive cement pastes after 0, 3, 7, 14, 21 and 49 days of being frozen at -80 ° C. In all cases the pastes were thawed and injected at 7 ° C.
Scalable invention to industrial application
The thermosensitive inorganic cements that have been described have several applications in the clinical and veterinary field, especially in the fields of orthopedic surgery, to fill bone cavities, cranial defects or cavities after removing a tumor, filling empty spaces after a fracture, fix screws when metal plates are placed, stabilize bone fractures or cover prostheses and implants, or in dentistry to fill gaps after removing a tooth or to increase the amount of bone before the placement of a dental implant. This invention is easily applicable on an industrial scale. The preparation of the powder and the liquid phase of the cements is very simple since all reagents are commercial and only the optimization of the particle size of the powder and the temperature of the paste is required in order to achieve the advantages listed below, which increase the value of said cement in the field of biomaterials.
(a) Minimization of the force necessary to inject the paste, facilitating the implantation process by injection;
(b) Obtaining total cohesion of the paste when it is injected at physiological temperature;
(c) Fast setting accompanied by high compressive strengths;
(d) Absence of toxic by-products;
(e) Adhesion to living tissues such as bone; f) Reabsorption in vivo.
10
fifteen
Also, the preparation of cement is simple. The use of cement in applications
Biomedical requires the sterilization of reagents as well as proper use of these.
In addition, the cement must be introduced into the bone or dental defect in a short, limited time
for the hardening of this.
REFERENCES
[1] G. Dumortier, JL Grossiord, F. Agnely, and JC Chaumeil, "A review of poloxamer 407 pharmaceutical and pharmacological characteristics.," Pharm. Res., Vol. 23, no. 12, pp. 2709-28, Dec. 2006.
[2] J. Franco, P. Hunger, ME Launey, a P. Tomsia, and E. Saiz, "Direct write assembly of calcium phosphate scaffolds using a water-based hydrogel.," Acta Biomater., Vol. 6, no .
1, pp. 218-28, Jan. 2010.
[3] J. Raymond and A. Schwarz, "Temporary embolization using inverse thermosensitive polymers," US Pat. App. 10 / 794,804, 2004.
[4] D. O’mahony and V. Garigapati, "Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same," US Pat. App. 13 / ..., 2013.
[5] M. P. Geneva, J. A. Planell, and F. X. Gil, "Injectable, Self Setting Calcium Phosphate Foam," EP20050782615 200508112007.

权利要求:
Claims (11)
[1]
5
10
fifteen
twenty
25
30
35
40
Four. Five
I. - A biomedical thermosensitive inorganic cement characterized in that it comprises an inorganic hydraulic cement and a poloxamer, which can be added either in the solid phase or in the liquid phase, said solid phase of the inorganic hydraulic cement comprises calcium phosphates, sodium and / or ammonium, calcium carbonates, calcium sulfates, magnesium oxide or any mixture thereof, and the liquid phase is water or an aqueous solution.
2- A cement according to claim 1 wherein the poloxamer is preferably incorporated into the liquid phase of the cement, which comprises distilled water or an aqueous solution.
[3]
3. - A cement according to claim 1, in which the self-binding component is tricalcium phosphate alpha.
[4]
4. - A cement according to claim 1 wherein the poloxamer used as an additive is poloxamer 407, characterized in that poloxamer 407 can be incorporated as a powder in the solid phase of the cement or preferably dissolved in the liquid phase of the cement.
[5]
5. - A cement according to claim 4 wherein the poloxamer 407 is incorporated into the liquid phase of the cement in a concentration between 10 and 30% by weight, preferably 20% by weight.
[6]
6. A cement according to claims 3 to 5 wherein the liquid phase of the cement is preferably an aqueous solution of Na2HPO4, with a concentration of less than 10% by weight, preferably 2.5% by weight.
[7]
7. - A cement according to claims 3 to 5 wherein the mixing of the liquid phase with the solid is carried out at a liquid-powder ratio between 0.15 and 1.0 mL / g, preferably between 0.2 and 0.4 mL / g.
[8]
8. - A process for the preparation of thermosensitive inorganic cement for biomedical applications where the liquid phase formed by a poloxamer hydrogel, at a temperature below 25 ° C and preferably below 12 ° C, is mixed with the powder phase of the cement, comprising calcium, sodium and / or ammonium phosphates, calcium carbonates, calcium sulfates, magnesium oxide or any mixture thereof.
[9]
9. - A process for the preparation of a thermosensitive inorganic cement for biomedical applications according to claim 8 wherein the powder phase is preferably at a temperature below 25 ° C, and more preferably below 12 ° C.
[10]
10. - A process for the preparation of a thermosensitive inorganic cement for biomedical applications according to claims 8 and 9 wherein the powder phase preferably comprises alpha tricalcium phosphate.
II. - A process for the preparation of a thermosensitive inorganic cement for biomedical applications according to claim 10 in which the mixing of the liquid phase with the solid is carried out at a liquid-powder ratio between 0.15 and 1.0 mL / g, preferably between 0.2 and 0.4 mL / g.
[12]
12. - A procedure for the preparation of thermosensitive inorganic cement for
Biomedical applications, according to claim 8, wherein the mixing of the powder with the phase
The liquid is preferably made in a high energy mixer.
[13]
13. - A procedure for the preparation of inorganic thermosensitive cement for
Biomedical applications, according to claim 8, wherein the paste once placed in the
Inside a syringe or similar device, it is frozen, preferably at temperatures equal to or below -20 ° C, for storage, and subsequently preferably thawed at less than 12 ° C for use in the clinical application.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US8168692B2|2012-05-01|Bone substitute compositions and method of use

---

ES2199185T3|2004-02-16|MATERIAL FOR REABSORBABLE OSEO IMPLANT AND AS A PROCEDURE FOR THE PRODUCTION OF THE SAME.

---

ES2558381T3|2016-02-03|Cement based on macroporous and highly reabsorbable apatite calcium phosphate

---

ES2595252T3|2016-12-28|Aqueous sterile injectable formulation based on cross-linked hyaluronic acid and hydroxyapatite for therapeutic use

---

ES2359526T3|2011-05-24|INJECTABLE AGENT FOR THE FILLING OF BONE HOLES.

---

ES2549218T3|2015-10-26|Absorbable hemostatic material for bone lesions and associated preparation method

---

ES2345399T3|2010-09-22|INJECTABLE COMPOSITE MATERIAL SUITABLE FOR USE AS A OSEO SUBSTITUTE.

---

US20120071884A1|2012-03-22|Mixing and dispensing apparatus for bone void filler

---

AU2003263719A1|2004-04-19|Heat generating biocompatible ceramic materials

---

BR102013034085B1|2020-09-24|BIOCOMPATIBLE AND REABSORBIBLE COMPOSITES FOR OSTEOSYNTHESIS AND ITS METHOD FOR MANUFACTURING

---

JP2002325831A|2002-11-12|Filling material for organism and manufacture thereof

---

TWI651103B|2019-02-21|Multiphase bone graft replacement material

---

WO2013163705A1|2013-11-07|Injectable bioactive and bioresorbable material, and method for preparing the injectable bioactive and bioresorbable material

---

ES2802374T3|2021-01-19|Multiple Ion Substitution Injectable Apatite Cement for Regenerative Vertebroplasty and Kyphoplasty

---

ES2553302B1|2016-09-14|INORGANIC, INJECTABLE AND THERMOSENSIBLE CEMENT FOR BONE RECONSTRUCTION: PREPARATION AND USE.

---

JP2004329458A|2004-11-25|Biomaterial aggregate/cement complex, and cement cured body

---

JP4224234B2|2009-02-12|Curing speed control method of hydration hardening type calcium phosphate paste for medical or dental use

---

ES2398309T3|2013-03-15|Dehydrated granular composition and its biomedical applications

---

이세호2007|Injectable bone substitute composed of biodegradable polymer/hydroxyapatite composite microspheres containing antibiotics

同族专利:

---

公开号 | 公开日

---

ES2553302B1|2016-09-14|

---

EP3144016A4|2018-01-10|

---

WO2015169992A1|2015-11-12|

---

EP3144016A1|2017-03-22|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US20060110357A1|2004-11-22|2006-05-25|Materna Peter A|Bone putty composition that maintains granule suspension at reduced temperatures|

---

CA2646486A1|2006-03-23|2007-09-27|Citagenix Inc.|Reverse phase osteoconductive composition|

---

EP1958649A1|2007-02-14|2008-08-20|Graftys|Injectable calcium-phosphate cement releasing a bone resorption inhibitor|

---

US20140030338A1|2011-03-03|2014-01-30|Spineart Sa|Product|CN111921002A|2020-08-06|2020-11-13|湖北联结生物材料有限公司|Antibacterial osteogenesis-promoting absorbable bone wax and preparation method thereof|

法律状态:
2016-09-14| FG2A| Definitive protection|Ref document number: 2553302 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160914 |

优先权:

---

申请号 | 申请日 | 专利标题

---

ES201430644A|ES2553302B1|2014-05-05|2014-05-05|INORGANIC, INJECTABLE AND THERMOSENSIBLE CEMENT FOR BONE RECONSTRUCTION: PREPARATION AND USE.|ES201430644A| ES2553302B1|2014-05-05|2014-05-05|INORGANIC, INJECTABLE AND THERMOSENSIBLE CEMENT FOR BONE RECONSTRUCTION: PREPARATION AND USE.|

---

PCT/ES2015/070361| WO2015169992A1|2014-05-05|2015-05-05|Inorganic, injectable and thermosensitive cement for bone reconstruction: preparation and use|

---

EP15789667.1A| EP3144016A4|2014-05-05|2015-05-05|Inorganic, injectable and thermosensitive cement for bone reconstruction: preparation and use|